P. fluorescens-based Pfenex Expression Technology® (Pfenex) transforms protein production through combinatorial screening to identify robust strains. With 20+ years of development and 6 marketed products, Pfenex excels where others fail. Launched in 2024, Pfast™ offers an affordable 10-day evaluation of protein titer and quality. Tested on 30+ partner proteins, Pfast significantly improved productivity challenges, enabling better pipeline management and seamless integration into existing capabilities.
Russell Coleman
Russ Coleman is the Director, Strain Engineering at Primrose Bio Inc. focused on delivering efficient and scalable high-throughput expression strain screening strategies to enable robust manufacturing solutions for next generation biotherapeutics and vaccines. For more than 20 years, Russ has been a big fan of Pseudomonas bacteria and a key contributor in the development of Primrose Bio’s industry-proven therapeutic protein production platform, the Pfenex Expression Technology®.